Alimera Sciences Inc reports results for the quarter ended in June - Earnings Summary

Alimera Sciences

08/08/2024 14:51

* Alimera Sciences Inc  ALIM.OQ  reported a quarterly
adjusted
loss of 6 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-1.32.  The mean expectation of four analysts
for the quarter was for a loss of 4 cents per share. Wall Street
expected results to range from -6 cents to -2 cents per share.
    * Revenue rose 54% to $27.00 million from a year ago;
analysts
expected $25.73 million. 
    * Alimera Sciences Inc's reported EPS for the quarter was a
loss
of 6 cents​.
    * The company reported a quarterly loss of $3.31 million.
    * Alimera Sciences Inc shares had fallen by 0.2% this
quarter and
gained 28.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 175.1% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Alimera Sciences
Inc is $5.50 
This summary was machine generated from LSEG data August 8 at
01:50 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.04          -0.06          Missed
 Mar. 31 2024      -0.06          -0.12          Missed
 Dec. 31 2023      0.00           -0.07          Missed
 Sep. 30 2023      -0.06          -0.06          Met